THU0212 FIRST LINE TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: A MULTINATIONAL POPULATION-BASED COHORT FROM 14 REAL …

AG Sena, D Granados,N Hughes, W Fakhouri, A Hottgenroth,R Kolde,S Reisberg,CO Torre,T Duarte-Salles,Y Díaz,JF Golib-Dzib,ES Brouwer,E Burn,J Lane,D Vizcaya,S Bruce Wirta,M De Wilde,K Verhamme, P Rijnbeek,E Theander, K Chatzidionysiou, D Prieto-Alhambra,P Ryan

Annals of the Rheumatic Diseases(2020)

引用 1|浏览15
暂无评分
摘要
Background: Treatment guidelines recommend early initiation of csDMARDs following diagnosis of rheumatoid arthritis (RA), with methotrexate (MTX) as first-line therapy. Scarce evidence exists on adherence to this guidanceObjectives: To characterize first-line csDMARD treatment during the first year following an RA diagnosis.Methods: 14 real world databases (3 Primary care, 6 primary/secondary care records, 5 claims) from 9 countries were included, all mapped to the OMOP common data model.Patients were included on the earliest event of: 1st diagnosis of RA or 1st DMARD prescription with an RA diagnosis within 30 days. Patients were >18 years-old, required 1+ year pre-index data, and at least 1-year follow-up. Study period covered 2000-2018. Previous users of DMARDs or non-RA inflammatory arthritis history were excluded. Only MTX, Hydroxychloroquine (HCQ), Sulfasalazine (SSZ) and Leflunomide …
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要